Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: An adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04)

Journal of Clinical Oncology

Volumn 31, Issue 21, 2013, Pages 2685-2691

  Rathbone, Emma J ^a,b   Brown, Janet E ^a,b   Marshall, Helen C ^b   Collinson, Michelle ^b   Liversedge, Victoria ^b   Murden, Geraldine A ^b   Cameron, David ^c   Bell, Richard ⁱ   Spensley, Saiqa ^d   Agrawal, Rajiv ^e   Jyothirmayi, Rema ^f   Chakraborti, Prabir ^g   Yuille, Frances ^h   Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d CASTLE HILL HOSPITAL   (United Kingdom)

^e ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^f MAIDSTONE HOSPITAL   (United Kingdom)

^g QUEEN S HOSPITAL   (United Kingdom)

^h NHS LOTHIAN   (United Kingdom)

ⁱ Andrew Love Cancer Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; JAW OSTEONECROSIS; MANDIBLE; MAXILLA; MOUTH; MOUTH DISEASE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CHEMICALLY INDUCED; CONTROLLED STUDY; HEALTH; JAW DISEASES; MIDDLE AGED; OSTEONECROSIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; JAW DISEASES; MIDDLE AGED; ORAL HEALTH; OSTEONECROSIS; QUALITY OF LIFE;

EID: 84890058802     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.4792     Document Type: Article

References (23)

1. Coleman RE, Marshall H, Cameron D, et al: Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405, 2011
2. Coleman R, de Boer R, Eidtmann H, et al: Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results. Ann Oncol 24:398-405, 2013
3. Paterson AHG, Anderson SJ, Lembersky BC, et al: NSABP Protocol B-34: A clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy - Final analysis. San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011 (abstr S2-S3)
4. Möbus V, Diel I, Elling D, et al: GAIN study: A phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer - First interim efficacy analysis. San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011 (abstr S2-S4)
5. Gnant M, Mlineritsch B, Stoeger H, et al: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631-641, 2011
6. Coleman R, Woodward E, Brown J, et al: Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat 127:429-438, 2011
7. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al: Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62:527-534, 2004
8. Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61:1115-1117, 2003
9. Slade GD: Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol 25:284-290, 1997
10. Slade GD, Nuttall N, Sanders AE, et al: Impacts of oral disorders in the United Kingdom and Australia. Br Dent J 198:489-493, 2005
11. Saad F, Brown JE, Van Poznak C, et al: Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341-1347, 2012
12. Ruggiero SL, Dodson TB, Assael LA, et al: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 67:2-12, 2009 (suppl 5)
13. Cohen JW: Statistical Power Analysis for the Behavioural Sciences. Hillsdale, NJ, Lawrence Erlbaum Associates, 1998, pp 12-25
14. Locker D: Measuring oral health: A conceptual framework. Community Dent Health 5:3-18, 1988
15. Walter C, Al-Nawas B, Grötz KA, et al: Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54:1066-1072, 2008
16. Migliorati CA, Epstein JB, Abt E, et al: Osteonecrosis of the jaw and bisphosphonates in cancer: A narrative review. Nat Rev Endocrinol 7:34-42, 2011
17. Ripamonti CI, Maniezzo M, Campa T, et al: Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates: The experience of the National Cancer Institute of Milan. Ann Oncol 20:137-145, 2009
18. Vandone AM, Donadio M, Mozzati M, et al: Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: A single-center clinical experience. Ann Oncol 23:193-200, 2012
19. Dimopoulos MA, Kastritis E, Bamia C, et al: Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117-120, 2009
20. Coleman R, Burkinshaw R, Winter M, et al: Zoledronic acid. Expert Opin Drug Saf 10:133-145, 2011
21. Brufsky AM, Harker WG, Beck JT, et al: Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118:1192-1201, 2012
22. Miksad RA, Lai KC, Dodson TB, et al: Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist 16:121-132, 2011
23. Sanders AE, Slade GD, Lim S, et al: Impact of oral disease on quality of life in the US and Australian populations. Community Dent Oral Epidemiol 37:171-181, 2009